Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

July 11, 2014

Source: Heart online first

Follow this link for fulltext

Date of publication: July 2014

Publication type: Research

In a nutshell: Results from the EMPHASIS-HF trial (‘Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure’) were used to develop a simulation model estimating lifetime direct costs of prescribing eplerenone to patients with chronic systolic heart failure (HF). Eplerenone was regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (Quality-Adjusted Life Years).

Length of publication: 7 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Advertisements

The cost effectiveness of ivabradine in the treatment of chronic heart failure

June 19, 2014

Source: Heart, 2014, 100 (13) p. 1031-6

Follow this link for fulltext

Date of publication: July 2014

Publication type: Journal article

In a nutshell: This economic evaluation assessed the cost-effectiveness of ivabradine from the perspective of the UK National Health Service, based on the results of the SHIfT trial. Ivabradine is expected to have a 95% chance of being cost-effective in the EU-licensed population using the current NICE cost-effectiveness threshold of £20,000 per QALY.

Length of publication: 6 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.